Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO Study (NGF0120)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05552261
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:54.949101+00:00
Published At
2025-11-28T00:00:00+00:00
Record Updated At
2025-11-28
Results Posted At
2025-11-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neurotrophic Keratitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-28"
protocolSection.identificationModule.nctId
"NCT05552261"
protocolSection.identificationModule.officialTitle
"A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE\u00ae 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO Study (NGF0120)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-11-28"

Study condition terms

  • Neurotrophic Keratitis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.